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Conventional chemotherapeutics and targeted antineoplastic agents have been developed based on the
simplistic notion that cancer constitutes a cell-autonomous genetic or epigenetic disease. However, it is
becoming clear that many of the available anticancer drugs that have collectively saved millions of life-years
mediate therapeutic effects by eliciting de novo or reactivating pre-existing tumor-specific immune
responses. Here, we discuss the capacity of both conventional and targeted anticancer therapies to enhance
the immunogenic properties of malignant cells and to stimulate immune effector cells, either directly or by
subverting the immunosuppressive circuitries that preclude antitumor immune responses in cancer patients.
Accumulating evidence indicates that the therapeutic efficacy of several antineoplastic agents relies on their
capacity to influence the tumor-host interaction, tipping the balance toward the activation of an immune
response specific for malignant cells. We surmise that the development of successful anticancer therapies
will be improved and accelerated by the immunological characterization of candidate agents.Introduction
Over decades, the development of antineoplastic drugs has
been based on the conviction that cancer would constitute a
cell-autonomous genetic and epigenetic disease (Hanahan and
Weinberg, 2011). Thus, chemotherapeutics have long been
viewed as a sort of antibiotics for malignant cells, i.e., chemicals
designed to preferentially target cancer cells and either limit their
proliferation or—preferably—cause their death. Based on this
consideration, academic and industrial drug developers gener-
ated agents that mediate cytostatic and/or cytotoxic effects
in vitro, on cultured human tumor cells, tested them on human
cancer xenografts growing in immunodeficient mice (a step
rendered obligatory by the US National Cancer Institute in
1979) (Zitvogel et al., 2008), assessed their pharmacological
and toxicological profiles (in preclinical models and in healthy
individuals), and eventually tested their actual therapeutic poten-
tial in clinical trials.
This ‘‘pipeline’’ has allowed for the introduction of highly
successful anticancer drugs into clinical practice, seemingly
justifying its overall design. For instance, specific therapeutic
regimens cure a very high fraction of patients affected by some
hematological malignancies, such as acute lymphoblastic
leukemia (Pui et al., 2009). Along similar lines, the use of anthra-
cyclines and oxaliplatin for the (adjuvant) treatment of breast and74 Immunity 39, July 25, 2013 ª2013 Elsevier Inc.colorectal cancer patients, respectively, has saved millions of
life-years and has significantly improved the long-term perspec-
tives of these individuals (Andre´ et al., 2004; Poole et al., 2006).
Finally, imatinib, which represents the first ‘‘targeted’’ anticancer
agent ever developed to specifically inhibit oncogenic signaling
cascades (including those driven by constitutively active ABL,
KIT, and PDGFR), has dramatically prolonged the life of tens of
thousands of patients with chronic myeloid leukemia (CML) or
gastrointestinal stromal tumors (GISTs) (Corless et al., 2011;
Druker et al., 2006).
Irrespective of these and other undeniable successes, the
traditional pipeline for the development of antineoplastic agents
is characterized by an enormous rate of attrition, meaning that
the vast majority (more than 95%) of agents that have been
selected in preclinical assays fails to exert robust therapeutic
effects in phase I/II clinical trials (Ocana et al., 2011). Moreover,
this traditional approach has been unable to identify drugs that
would significantly affect the clinical course of common and
quickly lethal malignancies such as lung and pancreatic cancer.
It is therefore tempting to ask whether the theoretical basis
underlying the current approach to the development of antineo-
plastic agents, namely, the vision of cancer as a purely cell-
autonomous disease, is correct or—at least—practical. Indeed,
this vision neglects the increasingly more accepted model
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Figure 1. Opposed Views of Oncogenesis and Tumor Progression
(A) Cancer has been viewed as a merely cell-intrinsic disease that develops
and progresses because of the accumulation of genetic and epigenetic
alterations.
(B) According to the immunoediting model, clinically manifest neoplasms
evolve through three distinct steps of interaction with the immune system:
(1) initially, malignant cells are recognized and eradicated by immune effector
cells (elimination phase), (2) at a later stage, small tumors are still held in check
by (increasingly less proficient) immune responses (equilibrium phase), and
(3) finally, neoplastic cells lose their antigenic properties or establish potent
immunosuppressive networks, thus avoiding any control by the immune
system (escape phase). The in-depth knowledge of the mutual interactions
between developing tumors and the immunosurveillance system will allow for
the identification of novel diagnostic, prognostic, and predictive biomarkers,
the discovery of novel targets and the optimization of therapeutic protocols
(in terms of doses and schedules), and the design of rational therapeutic
regimens combining chemo- and immunotherapeutic agents.
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immune system (a control mechanism that is generally referred
to as immunosurveillance) and can grow into clinically manifest
tumors only if they lose the immunogenic determinants that
make them recognizable by immune effectors (immunoselection)
or if they actively inhibit immune responses (immunosup-
pression) (Finn, 2008; Schreiber et al., 2011). Furthermore, the
therapeutic effects of the most successful anticancer agents
originate, at least in part, from elicitation of novel or the reactiva-
tion of pre-existing antitumor immune responses (Galluzzi et al.,
2012c; Zitvogel et al., 2011).Here, we evaluate the capacity of cytotoxic chemotherapeu-
tics and targeted anticancer agents that are currently employed
in clinical practice to reinstate immunosurveillance. In particular,
we differentiate between the direct immunogenic effects that
such therapeutic regimens exert on tumor cells and their capac-
ity to interact with the host immune system, resulting in
the reactivation of immune effectors or in the relief of immuno-
suppressive mechanisms. Most knowledge in this domain
stems from preclinical studies. Nonetheless, we briefly evaluate
clinical evidence supporting the notion that several successful
anticancer drugs mediate therapeutic effects by reinstating
immunosurveillance.
Clinical Evidence for Therapy-Induced
Immunosurveillance
The observation that cancer develops more frequently and more
aggressively in immunodeficient, as opposed to immunocompe-
tent, mice (Vesely et al., 2011) is paralleled by epidemiological
studies showing that transplant recipients (which are subjected
to chronic pharmacological immunosuppression) exhibit an
increased incidence of various neoplasms, including tumors
that a priori do not have a viral etiology (Bererhi et al., 2012;
Tjon et al., 2010; von Boehmer et al., 2012). These epidemiolog-
ical observations indicate that the immunosurveillance theory,
originally referring to mousemodels of immunodeficiency (which
are usually far more severe than human immunodeficiency syn-
dromes) (Vesely et al., 2011), does apply to human tumors, too.
The ‘‘three E’’ theory postulates that premalignant lesions are
generally eliminated by immune effectors, that small tumors
are in equilibrium with an ongoing (but increasingly less profi-
cient) anticancer immune response, and that neoplastic cells
finally escape from the immune control and form sizeable lesions
(Figure 1; Schreiber et al., 2011). Hence, tumors are usually diag-
nosed at the escape stage, which can occur by two distinct, yet
not mutually exclusive, mechanisms: (1) the selection of malig-
nant cells that have become unrecognizable by the immune sys-
tem (Matsushita et al., 2012; Senovilla et al., 2012) and (2) the
induction of a plethora of local and systemic immunosuppressive
mechanisms, encompassing the secretion of specific cytokines
such as interleukin-10 (IL-10) and the accumulation of immuno-
modulatory cell types including FOXP3+ regulatory T (Treg) cells,
myeloid-derived suppressor cells (MDSCs), and M2 macro-
phages (Coussens et al., 2013).
Robust evidence indicates the naturally occurring, pretherapy
anticancer immune responses significantly influence disease
progression in cancer patients. Thus, several parameters of the
immune infiltrate at diagnosis have been shown to correlate
with prognosis (and hence with the outcome of conventional
anticancer therapies) in patients affected by distinct types of
tumors (Fridman et al., 2012). In colorectal cancer (the most
extensively characterized tumor in this respect), the density,
composition, function, and architecture of immune cells infil-
trating primary lesions as well as metastatic sites, the so-called
tumor immune contexture, predict patient survival more accu-
rately than any other parameter, including the conventional
tumor node metastasis (TNM) classification (Galon et al., 2006;
Mlecnik et al., 2011). Along similar lines, an immunological score
based on the abundance of CD8+ T cells surrounding colorectal
cancer hepatic metastases has been shown to reliably predictImmunity 39, July 25, 2013 ª2013 Elsevier Inc. 75
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Reviewchemosensitivity (Halama et al., 2011). Some successful regi-
mens used for the treatment of colorectal cancer (such as the
combination of 5-fluorouracil with oxaliplatin or irinotecan) can
reduce the frequency of circulating Treg cells (Maeda et al.,
2011), thereby facilitating the elicitation of a primary or the boost-
ing of a secondary anticancer immune response. However, this
does not formally demonstrate whether local tumor-specific
immunity is elicited by chemotherapy. This enigma has been
resolved in the setting of breast carcinoma (BC).
The frequency of Treg cells infiltrating BC biopsies predicts the
long-term fate of patients receiving postoperative (adjuvant)
chemotherapy (Bates et al., 2006). FOXP3+ cells surrounding
neoplastic lesions appear to be particularly active, and their
abundance predicts disease relapse better than that of FOXP3+
cells infiltrating the tumor bed (Gobert et al., 2009). Along similar
lines, the infiltration of primary BC lesions by cells displaying a
CD4loCD8hiCD68lo profile (CD68 is a marker of macrophages
and plasmacytoid dendritic cells) is positively associated with
overall and relapse-free survival, irrespective of lymph node
involvement (DeNardo et al., 2011). The independent prognostic
value of intratumoral CD8+ T cell counts in BC patients has been
confirmed in additional studies (Mahmoud et al., 2011). More-
over, the amount of hematoxilin/eosin-detectable lymphocytes
infiltrating BC lesions at diagnosis constitutes an independent
predictive biomarker for the success of induction (neo-adjuvant)
chemotherapy, measured in terms of pathological complete
responses (pCRs) (Denkert et al., 2010; Loi et al., 2013a; West
et al., 2011). Accordingly, the expression of a set of immune
function-related genes (including several genes associated with
Th1 cells and interferon responses) or that of the constant chain
of immunoglobulin k (IGKC) has been shown to predict pCRs in
patients affected by all major BC subtypes, thereby increasing
the predictive power of clinicopathological parameters (Ignatia-
dis et al., 2012; Schmidt et al., 2012).
Several longitudinal studies have addressed the impact of
chemotherapy on the immune cells infiltrating BC lesions.
Thus, paclitaxel-based neoadjuvant chemotherapy has been
shown to increase the frequency of HE-detectable BC-infiltrating
lymphocytes, more so in patients who responded to chemo-
therapy (Demaria et al., 2001). Moreover, accumulating evidence
indicates that chemotherapy stimulates the infiltration of BCs by
myeloid and granzyme B-expressing cells while increasing the
intratumoral CD8+ to CD4+ T cell ratio (Ruffell et al., 2012). Of
note, an elevation in the intratumoral CD8+ to FOXP3+ T cell ratio
after one single cycle of anthracycline-based neoadjuvant
chemotherapy predicts the pCR to the entire chemotherapeutic
regimen (six cycles) (Ladoire et al., 2011; Senovilla et al., 2012).
These results may indicate that chemotherapy-elicited immune
responses are ultimately responsible for tumor eradication.
Immunological parameters also influence the fate of patients
receiving imatinib or similar tyrosine kinase inhibitors. For
instance, several biomarkers of natural killer (NK) cell activation
associate with the long-term therapeutic effects of imatinib in
GIST patients. These biomarkers include the expression of spe-
cific isoforms of the NK cell-activating receptor NKp30 (Delahaye
et al., 2011), the imatinib-induced production of interferon-g
(IFN-g) by circulating NK cells (Borg et al., 2004; Me´nard et al.,
2009), as well as the frequency of tumor-infiltrating NK cells
(Rusakiewicz et al., 2013). Moreover, GIST infiltration by T cells76 Immunity 39, July 25, 2013 ª2013 Elsevier Inc.constitutes an independent prognosticmarker and the prolonged
administrationof imatinib is associatedwith the lossofMHCclass
I variants by malignant cells, presumably constituting the result
of T cell-mediated immunoediting (Rusakiewicz et al., 2013). In
CML patients, imatinib-based therapeutic regimens induce
robust T cell responses as well as the secretion of tumor-specific
circulating IgMs (Catellani et al., 2011; Chen et al., 2008).
Altogether, these clinical findings suggest that—at least in
some settings—tumor-specific immune responses dictate the
fate of cancer patients. This notion is supported by ample
preclinical evidence indicating that transplantable, chemically
induced as well as oncogene-driven mouse cancers respond
more efficiently to a vast range of therapeutic modalities
in immunocompetent, as opposed to immunodeficient, hosts
(Table 1). A comprehensive compendium of chemotherapeutic
agents that mediate immunostimulatory effects can be found in
Galluzzi et al. (2012c) and Vanneman and Dranoff, (2012). As
discussed below, successful anticancer therapies can reinstate
immunosurveillance by modifying the propensity of malignant
cells to elicit an immune response or by exerting direct immunos-
timulatory effects (Figure 2).
Immunostimulation via Effects on Cancer Cells
Tumor debulking by surgery, radiotherapy, or chemotherapy
obviously reduces the systemic immunosuppressive activity of
malignant cells (Zitvogel et al., 2011). Beyond such a general
effect, clinically employed antineoplastic agents may stimulate
immunosurveillance by acting on cancer cells in several ways,
for example (1) by increasing the expression or presentation of
tumor-associated antigens on the surface of cancer cells (anti-
genicity), (2) by causing tumor cells to emit danger signals that
stimulate innate or cognate immune responses by operating as
adjuvants (immunogenicity), or (3) by augmenting the propensity
of tumor cells to be recognized and killed by immune effectors
(susceptibility) (Figure 3).
Enhanced Antigenicity
Cisplatin and gemcitabine broaden the range of tumor antigens
eliciting cytotoxic T lymphocyte (CTL) responses in vivo. Thus,
untreated ovalbumin-expressing mesotheliomas growing in
syngeneic C57BL/6 mice initially elicited an immune response
against the dominant epitope SIINFEKL that extended to a broad
spectrum of antigenic peptides upon chemotherapy, a phenom-
enon known as ‘‘epitope spreading’’ (Jackaman et al., 2012).
Conversely, some antineoplastic agents such as cyclophos-
phamide, gemcitabine, oxaliplatin, paclitaxel, and g irradiation
are known to exacerbate the antigenicity of cancer cells by
increasing the expression of MHC class I molecules (Chen and
Emens, 2013; Liu et al., 2010; Reits et al., 2006). Many chemo-
therapeutics including cisplatin, etoposide, paclitaxel, topote-
can, and vinblastine stimulate tumor cells to produce IFN-b,
which in turn operates as an autocrine factor to stimulate MHC
class I expression (Wan et al., 2012). Moreover, several anti-
cancer agents can specifically upregulate the expression of
tumor-associated antigens, including carcinoembryonic antigen
(which is responsive to 5-fluorouracil), various cancer testis anti-
gens (which are upregulated by 5-aza-20deoxycytidine and g
irradiation), and melanoma-associated antigens (which respond
to the BRAF inhibitor vemurafenib) (Chen and Emens, 2013;
Frederick et al., 2013; Sharma et al., 2011).
Table 1. Examples of FDA-Approved Anticancer Agents whose Efficacy Is Reduced by Immune Deficiencies
Agent Tumor Immune Defects Reference
5-fluorouracil EL4 lymphomas Nu/Nu genotype Vincent et al., 2010
anthracyclines CT26 colorectal carcinomas,
MCA205 fibrosarcomas,
MCA-induced tumors
Nu/Nu genotype, depletion of CD8+
or g/d T cells, blockade of CD11b,
neutralization of IL-1, IL-17, or IFN-g
Apetoh et al., 2007b; Casares et al., 2005;
Ghiringhelli et al., 2009; Ma et al., 2011, 2013;
Mattarollo et al., 2011; Obeid et al., 2007
ATRA ± arsenic trioxide murine APLs SCID phenotype Westervelt et al., 2002
arsenic trioxide CT26 colorectal cancers Nu/Nu genotype Thomas-Schoemann et al., 2012
cisplatin + digoxin MCA205 fibrosarcomas Nu/Nu genotype Menger et al., 2012
cyclophosphamide AB1-HA mesotheliomas Ifngr2/, Tnfsf10/, depletion
of CD8+ or NK cells
van der Most et al., 2009
dasatinib P815 mastocytomas depletion of CD4+ or CD8+ T cells Yang et al., 2012
gemcitabine AB12 mesotheliomas,
EJ-6-2 fibrosarcomas,
EL4 lymphomas, TC1
insulinomas
Nu/Nu genotype Suzuki et al., 2007; Vincent et al., 2010
imatinib AK7 mesotheliomas,
B16 melanomas,
RMA-S lymphomas
depletion of NK cells Borg et al., 2004
GISTs developing in
KitV558/+ mice
Rag1/, depletion of CD8+ T cells Balachandran et al., 2011
mitomycin C + digoxin MCA205 fibrosarcomas Nu/Nu genotype Menger et al., 2012
oxaliplatin CT26 colorectal carcinomas,
MCA205 fibrosarcomas
Nu/Nu genotype Michaud et al., 2011; Tesniere et al., 2010
paclitaxel Ret-driven melanomas depletion of CD8+ T cells Sevko et al., 2013
PLX4720 (BRAF inhibitor) SM1WT1 melanomas Ccr2/, Ifng/Prf1/, depletion
of CD8+ T cells
Knight et al., 2013
Abbreviations are as follows: APL, acute promyelocytic leukemia; ATRA, all-trans retinoid acid; IFN, interferon; IL, interleukin; MCA, 3-methylcholan-
threne; NK, natural killer; SCID, severe combined immunodeficient.
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I-restricted peptides that are expressed on the surface of
malignant cells, an effect that may stem—at least in part—from
mammalian target of rapamycin (mTOR)-transduced signals
(Reits et al., 2006). This is in line with the fact that the inhibition
of mTOR induces major alterations in the composition of the
MHC class I immunopeptidome (Caron et al., 2011). MHC class
I-associated peptides preferentially derive from so-called defec-
tive ribosomal products (DRiPs), i.e., short, abortive polypep-
tides that frequently originate from the translation of microRNA
(miRNA)-bound mRNAs (Granados et al., 2012). This suggests
that the probability of a given peptide to be presented on the sur-
face of tumor cells depends on (1) the primary sequence of the
corresponding gene (which is often mutated in cancer cells),
(2) the abundance of the corresponding transcript, and (3) the
levels of regulatory miRNAs. Thus, chemotherapy-inducedmod-
ifications in the expression of mRNAs and miRNAs (Salmena
et al., 2011) may profoundly influence the antigenicity of malig-
nant cells. This hypothesis warrants further in-depth evaluation.
Improved Immunogenicity
In response to chemotherapeutics, malignant cells can dispatch
a series of signals to alert not only their neighbors but also the
entire organism of incipient danger. Thus, cancer cells that
succumb to antineoplastic agents emit an entire spectrum of
cell death-associated molecules (CDAMs), some of which exert
potent adjuvant effects (Galluzzi et al., 2012a; Zitvogel et al.,
2010). For a long time, apoptosis has been considered as animmunologically silent (if not tolerogenic) cell death mode,
whereas necrosis was ascribed with proinflammatory and
immunogenic properties. In contrast to this dogma, however,
some instances of apoptosis—such as those induced by radio-
therapy and some chemotherapeutics—appears to bemore effi-
cient than necrosis—as induced by freeze-thawing or osmotic
lysis—at eliciting tumor-specific adaptive immune responses,
reflecting the fact that the clearance of apoptotic and necrotic
cells in vivo is rather different (Kroemer et al., 2013; Krysko and
Vandenabeele, 2010; Ravichandran, 2011). On the other hand,
the robust inflammatory responses associated with necrosis
may even exert protumorigenic effects (Coussens et al., 2013).
This said, cryoablation-induced necrosis has recently been
shown to yield robust antitumor immunity if accompanied by
appropriate immunostimulatory measures (such as the neutrali-
zation of cytotoxic T lymphocyte antigen 4 [CTLA4]) (Waitz et al.,
2012), implying that neither of the main cell death modalities is
intrinsically tolerogenic (Galluzzi et al., 2012e). Thus, the capacity
of dying and dead cancer cells to elicit a specific immune
response appears to be dictated by CDAMs rather than by
intrinsic features of apoptosis and necrosis. A number of CDAMs
exposed on the surface of dying cells or released into their
microenvironment, including calreticulin (CRT), ATP, high
mobility group box 1 (HMGB1), and several other factors, exert
potent immunostimulatory effects.
CRT is an abundant chaperone of the endoplasmic reticulum
(ER) that can be exposed on the cell surface in response toImmunity 39, July 25, 2013 ª2013 Elsevier Inc. 77
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Figure 2. Effects of Conventional and Targeted Antineoplastic
Agents on Tumor-Specific Immune Responses
As it depletes effector and suppressor immune cells, chemotherapy ‘‘resets’’
the immune system, thereby establishing a new immune repertoire. In addi-
tion, chemotherapy can mediate a multipronged immunostimulatory effect,
thereby reinstating anticancer immunosurveillance. On one hand, antineo-
plastic agents can increase the antigenicity of malignant cells, improve their
immunogenicity, and augment their susceptibility to immune attacks. On the
other hand, chemotherapy can directly promote the activation of immune
effector cells and/or inhibit immunosuppressive networks.
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Reviewmultiple perturbations of reticular homeostasis. The CRT expo-
sure pathway elicited by anthracyclines in tumor cells is complex
and relies on paracrine signals (for the most part conveyed by
chemokines such as IL-8), as well as on the activation of a multi-
pronged signal transduction cascade. Such signaling pathway
involves (1) the phosphorylation of eukaryotic initiation factor
2a (eIF2a) by the ER stress-sensing kinase PKR-related ER
kinase (PERK), (2) the activation of components of the apoptotic
pathway (including caspase-8, BAX, and BAK), (3) the antero-
grade transport of ER-derived vesicles through the Golgi appa-
ratus, and (4) the SNAP receptor (SNARE)-dependent exocytosis
of these vesicles (Panaretakis et al., 2009; Sukkurwala et al.,
2013). Other stimuli (e.g., hypericin-based photodynamic ther-
apy) can cause CRT exposure through a distinct, more rapid
pathway that relies on PERK but not on caspase-8 (Garg et al.,
2012). Once on the cell surface, CRT serves as an ‘‘eat-me’’
signal, stimulating the engulfment of dying tumor cells and their
apoptotic debris by macrophages and immature dendritic cells
(DCs) (Gardai et al., 2005; Ma et al., 2013; Obeid et al., 2007).
Chemotherapeutic agents that are able to trigger immuno-
genic cell death (ICD), i.e., a functionally peculiar type of
cellular demise that can stimulate protective anticancer immune
responses (Kroemer et al., 2013), are also efficient inducers of
CRT exposure. This applies to anthracyclines (e.g., doxorubicin,
mitoxantrone), oxaliplatin, and mafosfamide, the active meta-
bolite of cyclophosphamide (Obeid et al., 2007; Schiavoni
et al., 2011; Tesniere et al., 2010) Conversely, antineoplastic
agents that fail to induce CRT exposure (e.g., cisplatin, mito-
mycin C) are intrinsically incapable of provoking ICD and thus
promote suboptimal therapeutic effects. Structurally related78 Immunity 39, July 25, 2013 ª2013 Elsevier Inc.agents such as oxaliplatin and cisplatin differ in their ability to
induce CRT exposure and ICD. Whereas oxaliplatin can trigger
an ER stress response leading to CRT exposure independently
from its effects on nuclear DNA (Panaretakis et al., 2009),
cisplatin is a relatively weak inducer of ER stress (Tesniere
et al., 2010). Thus, cytoplasmic off-target effects may determine
the differential capacity of DNA-damaging agents to induce ICD.
Salubrinal (Obeid et al., 2007), thapsigargin (Martins et al., 2011),
and cardiac glycosides (Menger et al., 2012) have been success-
fully employed to restore CRT exposure (they all operate as ER
stress inducers), thereby improving the therapeutic profile of
cisplatin or mitomycin C. Of note, malignant cells that have
been depleted of CRT by RNA interference (RNAi) generate
lesions that fail to respond to chemotherapy in vivo, unless
recombinant CRT is exogenously provided i.t. (Panaretakis
et al., 2009). Conversely, cancer cells engineered to express a
variant of CRT that is constitutively exposed on the cell surface
are intrinsically immunogenic and can form tumors in vivo only
if they lose CRT expression (Senovilla et al., 2012). These results
underscore the important contribution of cell surface-exposed
CRT to anticancer immune responses.
ATP molecules released by dying cells constitute a potent
chemotactic signal for myeloid cells including monocytes/
macrophages (Elliott et al., 2009) and DC precursors (Ma et al.,
2013). Cancer cells respond to ICD inducers by secreting ATP
through a mechanism that involves the caspase-dependent
activation of pannexin 1 channels, lysosomal exocytosis, and
plasma membrane blebbing (Elliott et al., 2009; Martins et al.,
2013). The upregulation of autophagy is required for ATP release
by dying cancer cells (Michaud et al., 2011), presumably
because autophagy maintains high ATP concentrations within
autophagosomes in the course of stress responses (Martins
et al., 2013). Thus, autophagy-deficient tumors exposed to
chemotherapy are unable to attract tumor-infiltrating leukocytes
and therefore fail to induce therapeutic anticancer immune
responses (Michaud et al., 2011). Of note, autophagy is
frequently disabled during early oncogenesis (Morselli et al.,
2009; White, 2012), perhaps helping incipient tumors to evade
immunosurveillance.
The transfection-enforced expression ofCD39 (an ectonucleo-
tidase that degrades ATP to ADP and AMP) on tumor cells abol-
ishes the therapeutic activity of multiple antineoplastic agents
(Michaud et al., 2011, 2012). Another ectonucleotidase, CD73,
can convert AMP into adenosine, which exerts prominent immu-
nosuppressive effects (Beavis et al., 2012). The pharmacological
inhibition of CD39 improves the response to chemotherapy of
autophagy-deficient tumors, presumably by increasing pericellu-
lar ATP concentrations and thereby restoring immune infiltration
(Michaud et al., 2011). Similarly, CD73-null mice exhibit improved
antitumor immune responses and are relatively resistant to the
development of metastases (Beavis et al., 2012; Stagg et al.,
2011), an effect that appears to involve both hematopoietic and
nonhematopoietic cell compartments (Stagg et al., 2011). In
line with these notions, high expression levels of CD39 and
CD73 correlate with poor disease outcome in patients affected
by chronic lymphocytic leukemia (Pulte et al., 2011), colorectal
carcinoma (Wu et al., 2012), and estrogen receptor-negative,
progesterone receptor-negative, and HER2-negative (triple
negative) BC. In this latter context, robust CD73 expression
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Figure 3. Effects of Anticancer Agents on Tumor Antigenicity,
Immunogenicity, and Susceptibility to Immune Attacks
(A) Conventional chemotherapeutics as well as targeted anticancer agents
can stimulate the expression of MHC class I molecules and expand the
range of antigenic epitopes exposed on the surface of malignant cells
(‘‘epitope spreading’’). This alters the MHC class I immunopeptidome of
cancer cells and thereby increases their propensity to be recognized by a/b
T cells.
(B) Several distinct antineoplastic agents improve the immunogenicity of
malignant cells as they stimulate them to emit various immunostimulatory
signals, including calreticulin (CRT), ATP, and high mobility group box 1
(HMGB1). Upon binding to specific receptors on the surface of dendritic cells
and other cells of the immune system, these signals promote the uptake,
processing, and presentation of antigens, favor chemotaxis, and stimulate the
secretion of immunostimulatory cytokines.
(C) Chemotherapy can alter the surface proteome of cancer cells so that they
become more susceptible to the cytotoxic activity of several innate and
adaptive immune effectors. Abbreviations are as follows: DR, death receptor;
DRiPs, defective ribosomal products; ER, endoplasmic reticulum; NK, natural
killer; NKT, natural killer T; TLR4, Toll-like receptor 4.
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therapy (Loi et al., 2013b).
Extracellular ATPacts onpurinergic receptors of distinct types,
including metabotropic P2RY2 and ionotropic P2RX7 receptors.
P2RY2-conveyed signals are required for the recruitment, persis-
tence, and differentiation of DC precursors and neutrophils into
the tumor bed (Elliott et al., 2009; Ma et al., 2013). In addition,
by binding P2RX7 receptors on the surface of DCs, ATP stimu-
lates the NLRP3 inflammasome-dependent production of IL-1b,
thereby skewing the polarization of subsequent T cell responses
toward a cytotoxic TC1 pattern (Ghiringhelli et al., 2009). Anti-
bodies that neutralize IL-1b as well as recombinant IL-1 receptor
antagonists abolish the efficacy of anticancer chemotherapies
and prevent tumor infiltration by IL-17-producing gd T cells and
IFN-g-producing CD8+ ab T cells (Ghiringhelli et al., 2009; Ma
et al., 2011; Mattarollo et al., 2011). Moreover, anthracycline-
treated BC patients with a loss-of-function P2RX7 allele have
been shown to developmetastasesmore rapidly than individuals
bearing two normal copies of the gene (Ghiringhelli et al., 2009).
Taken together, these observations suggest that ATP and puri-
nergic receptor signaling play a decisive role in chemotherapy-
elicited anticancer immune responses.
HMGB1 is a nonhistone chromatin-binding factor that can
be released by dead cells through permeabilized nuclear and
plasma membranes. Perhaps depending on posttranslational
modifications including redox-dependent changes (Kazama
et al., 2008; Venereau et al., 2012), extracellular HMGB1 can
interact with several distinct pattern recognition receptors,
including advanced glycosylation end product-specific receptor
(AGER) and Toll-like receptor 4 (TLR4) (Bianchi, 2009). In the
context of anticancer chemotherapy, the binding of extracellular
HMGB1 to TLR4 on the surface of DCs stimulates a MYD88 (but
not TRIF)-dependent signaling pathway, leading to optimal anti-
gen presentation (Apetoh et al., 2007b). Presumably, this is due
to the fact that TLR4 signals prevent the premature lysosomal
degradation of engulfed apoptotic debris and tumor-associated
antigens (Apetoh et al., 2007b). Tumors that lack HMGB1 and
evolve in normal hosts, as well as tumors that do express
HMGB1 and grow in Tlr4/ or Myd88/ mice, fail to respond
to anthracycline-based chemotherapy (Apetoh et al., 2007b;
Yamazaki et al., 2013). In this context, therapeutic responses
can be restored by a variety of strategies, including the provision
of alternative DC activation signals (e.g., the TLR3 agonist
poly(I:C), semisynthetic TLR4 agonists such as dendrophilin
A and S) and the short-term inhibition of lysosomal degradation
with chloroquine (Apetoh et al., 2007b; Yamazaki et al., 2013).
BC progression is often accompanied by the loss of tumoral
HMGB1 expression (Yamazaki et al., 2013), a trait that has
been correlated with poor survival in esophageal squamous
cell carcinoma patients (Suzuki et al., 2012). Along similar lines,
a loss-of-function TLR4 allele has been shown to negatively
affect the prognosis of BC patients receiving adjuvant anthracy-
clines (Apetoh et al., 2007b) and stage II colorectal cancer
patients treated with oxaliplatin-based chemotherapy (Tesniere
et al., 2010). Thus, HMGB1 and TLR4 play a major role in the
elicitation of anticancer immune responses.
Anticancer agents such as cyclophosphamide, oxaliplatin,
and gemcitabine can induce tumor cells to emit signals
that stimulate DC maturation (Liu et al., 2010; SchiavoniImmunity 39, July 25, 2013 ª2013 Elsevier Inc. 79
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usually does not prevent DC maturation (L.Z. and G.K., data
not shown), pointing to the existence of alternative players in
this process. These factors may include HSP90, which is
exposed on the surface of myeloma cells responding to the
proteasomal inhibitor bortezomib (Spisek et al., 2007), as well
as several mitochondrial products that are released upon
necrotic plasma membrane permeabilization (Galluzzi et al.,
2012a). Several antineoplastic agents have been shown to
induce the differentiation of DC precursors and/or to promote
DC maturation, including anthracyclines (van de Ven et al.,
2012), vinca alkaloids (Tanaka et al., 2009), and other agents
(Kaneno et al., 2009). Whether these effects require a fraction
of cells to die (thereby releasing factors that stimulate DC dif-
ferentiation or maturation) has not been clarified. In response
to anthracycline-based chemotherapy, DC precursors have
been shown to infiltrate the tumor bed, localize in the close
proximity of nests of dying cancer cells, and mature (Ma
et al., 2013). This may be critical for the re-establishement of
immunosurveillance, as indicated by the fact that tumor-infil-
trating immature DCs expressing PD-L1 have been involved
in local immunosuppressive networks (Engelhardt et al., 2012;
Krempski et al., 2011).
Increased Susceptibility to Immune Attacks
There are multiple mechanisms through which antineoplastic
agents can increase the susceptibility of malignant cells to the
cytotoxic activity of immune effectors.
A large panel of chemotherapeutics including most DNA-
damaging agents has been shown to stimulate the expression
of death receptors, including FAS (also known as CD95)
and TNF-related apoptosis-inducing ligand (TRAIL) receptors 1
and 2 (TRAIL-R1 and TRAIL-R2), on the surface of tumor cells.
In the presence of their ligands, death receptors elicit an intracel-
lular signaling cascade leading to apoptotic or necrotic cell death
(Vandenabeele et al., 2010). Hence, chemotherapymay sensitize
cancer cells to the induction of cell death by FAS ligand (FASL)
or TRAIL, which are produced by a variety of immune effectors
(Ashkenazi and Dixit, 1998; Hellwig and Rehm, 2012). TRAIL
appears to induce immunogenic cell death (Panaretakis
et al., 2009), thereby amplifying ongoing anticancer immune
responses. FAS signaling also favors the secretion of multiple
cytokines and chemokines, including CXCL1, CCL2, IL-6, and
IL-8. IL-8 not only promotes an ATP-independent chemotactic
response of phagocytes toward apoptotic cells (Cullen et al.,
2013), but also stimulates CRT exposure (Sukkurwala et al.,
2013). Therefore, it is possible that death receptor signaling
can induce hallmarks of immunogenic cell death indirectly, via
the production of IL-8.
A range of different stress conditions can stimulate the expo-
sure of ligands for NK cell-activating receptors (e.g., NKG2D,
DNAM-1) on the surface of malignant cells (Chan et al., 2010;
Raulet et al., 2013). In doing so, distinct DNA-damaging agents
(Soriani et al., 2009), histone deacetylase inhibitors (Berghuis
et al., 2012), and lenalidomide (Benson et al., 2011) reportedly
increase the susceptibility of cancer cells to lysis by specific
lymphocyte populations (mostly NK, NKT, and gd T cells)
(Chan et al., 2010; Raulet et al., 2013). Whether this mechanism
contributes to the eradication of neoplastic cells responding to
chemotherapy in vivo remains to be elucidated.80 Immunity 39, July 25, 2013 ª2013 Elsevier Inc.Various anticancer agents including paclitaxel, cisplatin, and
doxorubicin have been shown to sensitize mouse cancer cell
lines to the cytotoxic functions of CTLs by increasing the expres-
sion of mannose-6-phosphate receptor (M6PR) on the cell sur-
face. M6PR augments the permeability of the plasmamembrane
to granzyme B, one of the main CTL effector molecules, and
thereby renders tumor cell killing by CTLs independent from per-
forin (Ramakrishnan et al., 2010). In line with this notion, perforin
is not absolutely required for chemotherapy to exert optimal anti-
neoplastic effects (Kroemer et al., 2013), in particular inmodels in
which the therapeutic outcome clearly depends on CD8+ T cells
(Ghiringhelli et al., 2009). The redistribution of M6PR to the
surface of neoplastic cells exposed to chemotherapy appears
to be linked to autophagy, as indicated by the fact that the
siRNA-mediated knockdown of the essential autophagic medi-
ator Atg5 abolishes this effect (Ramakrishnan et al., 2012).
Thus, autophagy may be required for optimal chemotherapeutic
responses not only as it promotes the emission of a chemotactic
and immunostimulatory signal (ATP, see above), but also as it
increases the susceptibility of tumor cells to lysis by CTLs.
Chemotherapy can induce the expression of costimulatory
molecules such as CD80 (also known as B7-1) on the surface
of malignant cells or downregulate immunosuppressive mole-
cules such as PDL1, PDL2, and VTCN1 (also known as B7-H1,
B7-DC, and B7-H4, respectively) (Chen and Emens, 2013).
This is the case of lenalomide, which has been shown to upregu-
late various costimulatory molecules (i.e., CD80, CD83, CD86)
on the surface of tumor cells while downregulating PDL1
(Chanan-Khan et al., 2012), and various platinum derivatives,
which reportedly reduce the cell surface expression of PDL2
by activating STAT6 (Lesterhuis et al., 2011).
GISTs are often driven by gain-of-function mutations in the
gene coding for the tyrosine kinase KIT and therefore can be
treated with imatinib. The administration of imatinib to GIST-
bearing mice results in the downregulation of indoleamine 2,3-
dioxygenase, an enzyme that catalyzes the synthesis of kynure-
nine. Because kynurenine constitutes an obligate trophic factor
for Treg cells, imatinib limits tumor infiltration by these immuno-
suppressive cells and hence promotes anticancer immune
responses mediated by T and NK lymphocytes (Balachandran
et al., 2011; Rusakiewicz et al., 2013).
Taken together, these observations indicate that successful
antineoplastic agents can elicit therapeutic immune responses
as they increase the antigenicity of malignant cells, their immu-
nogenicity, or their susceptibility to effector mechanisms.
Effects of Anticancer Agents on the Immune System
Many anticancer agents are clinically employed at their
maximum tolerated dose, at which they can exert potent myelo-
suppressive and/or lymphoablative side effects, most often
resulting in a transient state of systemic immunosuppression.
Such regimens can deplete both effector and suppressor cells
and can impose the creation of new immune repertoires (Finn,
2012), thus ‘‘resetting’’ the immune system. Nevertheless, anti-
cancer agents used at clinically efficient doses (which are usually
well below the maximum tolerated dose) may mediate rapid
immunostimulatory effects (Galluzzi et al., 2012c). For instance,
the vaccination of cancer patients receiving standard-of-
care chemotherapy can result in vigorous immune responses
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the notion that chemotherapeutics invariably promote severe
immunosuppression. Moreover, the results of multiple clinical
studies suggest that the CTLA4-targeting antibody ipilimumab
can be advantageously combined with various antineoplastic
agents such as fotemustine and temozolomide (for the treatment
of metastatic melanoma patients) or paclitaxel plus carboplatin
(in individuals bearing non-small-cell lung carcinoma) (Lynch
et al., 2012; Maio et al., 2013). Obviously such combinatorial
treatments would not be effective if chemotherapy resulted in
severe immunosuppression.
Paradoxically, the two most commonly used taxanes, pacli-
taxel and docetaxel, have been shown to mediate immunosti-
mulatory effects in mice, hence increasing immune responses
against the model antigen ovalbumin or an influenza H1N1
virus-specific vaccine (Chen et al., 2012; Yuan et al., 2010). Pacli-
taxel enhances the efficacy of various other immunotherapeutic
regimens, including multiple immunocytokines (e.g., IL-2, IL-7,
or IL-12 variants targeted to the tumor vasculature by a specific
monoclonal antibody) (Moschetta et al., 2012; Pasche et al.,
2012) as well as HER2 and vascular endothelial growth factor
(VEGF) peptide mimics (Foy et al., 2012). In doing so, paclitaxel
allows for the activation of immune responses that—at least in
some murine models of cancer—successfully eradicate malig-
nant cells (Moschetta et al., 2012; Pasche et al., 2012). Along
similar lines, docetaxel has been shown to improve the thera-
peutic potential of an immunotherapeutic regimen combining
adoptive T cell transfer and DC-based vaccination (Galluzzi
et al., 2012b, 2012d; Kodumudi et al., 2012). Backing up these
preclinical observations, sporadic evidence from clinical trials
suggests that cancer patients who have previously been treated
with immunotherapy respond better to salvage chemotherapy
than do patient who have not (Vanneman and Dranoff, 2012).
Antineoplastic agents may promote tumor-specific immune
responses in several ways. However, inmany studies it is difficult
to distinguish whether the apparent immunostimulatory effects
of chemotherapy, which are paralleled by changes in the
immune infiltrate (most frequently an increase in effector cells
coupled to a reduction in immunosuppressive cells) are truly
therapeutic or simply represent a consequence of tumor debulk-
ing. Therefore, we focus on anticancer agents that have been
ascribed with immunostimulatory activity in the absence of
tumors.
Stimulation of Innate Immune Effectors
Bisphosphonates (e.g., zoledronate, which is mainly used for the
treatment of osteolytic metastases) activate caspase-1 in DCs
by depriving them of prenylpyrophosphates. In doing so,
bisphosphonates stimulate DCs to produce IL-1b and IL-18,
which in turn favor the secretion of IFN-g by NK cells and gd
T cells (Nussbaumer et al., 2011). Subcytotoxic doses of doxo-
rubicin, methotrexate, mitomycin C, and paclitaxel directly
upregulate the antigen-presenting functions of isolated DCs as
well as the expression of CD40, CD80, CD86, and MHC class
II molecules on their surface (Shurin et al., 2009).
In vivo, imatinib reportedly reduces the growth ofmouse tumor
cells that are refractory to its antineoplastic activity in vitro, an
effect that is abolished upon NK cell depletion (Borg et al.,
2004; Taieb et al., 2006). Accordingly, imatinib potently stimu-
lates NK cells in vivo (but not in vitro) via an indirect mechanismthat involves the inhibition of KIT signaling in DCs (Borg et al.,
2004; Delahaye et al., 2011). Dasatinib, another tyrosine kinase
inhibitor, has also been shown to mobilize NK cells, thereby
improving their cytotoxicity in CML patients (Mustjoki et al.,
2013).
Activation of T Cells
The BRAF inhibitors GSK2118436 and vemurafenib increase the
infiltration of humanmelanomasbyCD4+ andCD8+granzyme-B-
expressing ab T cells, correlating with a reduction in tumor size
(Wilmott et al., 2012). The RNAi-mediated depletion of oncogenic
BRAFV600E can reduce the secretion of immunosuppressive sol-
uble factors such as IL-6, IL-10, and VEGF by melanoma cells
(Sumimoto et al., 2006). Along similar lines, PLX4720, another
BRAF-targeting agent, has been shown to downregulate the
production of CCL2 by both transplantable BRAFV600E-driven
and de novo melanomas, resulting in robust tumor infiltration
by CD8+ T cells and prominent antineoplastic effects (Knight
et al., 2013). These observations suggest that (1) at least in
somesettings, the chemotactic functions ofCCL2 (which recruits
potentially immunosuppressivemacrophages) predominate over
its immunostimulatory capacity and (2) BRAF inhibitors mediate
immunostimulatory effects by targeting tumor cells. In line with
this notion, vemurafenib reportedly improves the effector func-
tions of tumor antigen-specific T cells adoptively transferred to
melanoma-bearing mice through mechanisms that cannot be
recapitulated with isolated T cells (Koya et al., 2012).
Other chemotherapeutic agents may directly stimulate
immune effectors. For instance, cyclophosphamide promotes
the differentiation of human and murine Th17 cells, in vitro and
in vivo, an effect that can be detected among circulating as well
as tumor-infiltrating lymphocytes (Viaud et al., 2011). Taxanes
stimulate the production of IFN-g and IL-2 by T cells, presumably
favoring T cell polarization toward a Th1 cell profile (Tsavaris
et al., 2002). Bisphosphonates increase the proliferation and
cytotoxic activity of Vg9Vd2 T cells by acting either on DCs or
on tumor cells, presumably owing to the accumulation of isopen-
tenyl pyrophosphate (Cabillic et al., 2010). Such Vg9Vd2 T cells
can directly kill malignant cells (Benzaı¨d et al., 2011) or elicit
CTL responses specific for tumor-associated antigens (Altvater
et al., 2012). At present, it is not knownwhether bisphosphonates
preferentially act on neoplastic lesions or whether they predom-
inantly exert systemic effects.
Inhibition of Myeloid-Derived Suppressor Cells and M2
Macrophages
MDSCs and M2 macrophages exert robust tumor-supporting
functions as they contribute to the establishment of an immuno-
suppressive local microenvironment (Coussens et al., 2013).
Several chemotherapeutic agents appear to reduce the amount
or inhibit the activity of these cells, tipping the balance toward
the activation of antitumor immune responses.
Gemcitabine, a nucleosideanalog, specifically reduces splenic
MDSCs (Gr-1+/CD11b+ cells) in tumor-bearing mice, while leav-
ing the effector functions of local NK cells unaffected (Suzuki
et al., 2005). Similar MDSC-depleting effects in both the spleen
and the tumor microenvironment have been ascribed to another
nucleoside analog, 5-fluorouracil (Vincent et al., 2010).Moreover,
gemcitabine increases the absolute and relative abundance
of circulating CD14+ monocytes and CD11c+ myeloid DCs in
pancreatic carcinoma patients (Soeda et al., 2009).Immunity 39, July 25, 2013 ª2013 Elsevier Inc. 81
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in vitro (Michels et al., 2012). Along similar lines, docetaxel has
been reported to decrease splenic MDSCs in mice bearing
mammary tumors (Kodumudi et al., 2010) as well as intratumoral
MDSCs in mice developing transgene-induced melanomas, an
effect that was paralleled by the reduction of local proinflamma-
tory and immunosuppressive factors such as transforming
growth factor b (TGF-b) and IL-10 (Sevko et al., 2013). The
MDSC-depleting activity of docetaxel is linked to the induction
of cell death in MDSCs bearing the M2 marker CD206 (but not
in their counterparts expressing the M1 marker CCR7) (Sevko
et al., 2013) as well as to the acquisition of macrophage/DC
markers such as MHC class II molecules, CD11c, and CD86
by splenocytes (Kodumudi et al., 2012). Docetaxel also inhibits
the repopulation of the spleen by MDSCs upon total body irradi-
ation (Kodumudi et al., 2012). By inhibiting ABL, imatinib can
reduce the FcgR-mediated phagocytosis of murine macro-
phages, and this may contribute to its broad anti-inflammatory
activity (Greuber and Pendergast, 2012). Whether this particular
effect contributes to the antineoplastic potential of imatinib
remains to be determined.
Suppression of FOXP3+ Regulatory T Cells
Cyclophosphamide is now widely acknowledged as an agent
that subverts the immunosuppressive functions of Treg cells,
especially when used at relatively low, so-called metronomic,
doses (Ghiringhelli et al., 2007; Le and Jaffee, 2012). Arsenic
trioxide, paclitaxel, and the VEGF receptor (VEGFR) inhibitor
sunitinib have also been shown to reduce the numbers of Treg
cells, at least in some experimental settings (Le and Jaffee,
2012). Similarly, oxaliplatin (but not irinotecan, 5-fluorouracil, or
gemcitabine) combined with IL-12 can increase the CTL to
Treg cell ratio within the hepatic metastases and in the spleen
of mice bearing transplantable colon carcinomas (Gonzalez-
Aparicio et al., 2011). The CTL to Treg cell ratio also increases
in melanomas responding to PLX4720 (Knight et al., 2013) as
well as in BCs responding to anthracycline-based chemotherapy
(Ladoire et al., 2011; Senovilla et al., 2012, 2013). Both cyclo-
phosphamide and gemcitabine (but neither 5-fluoruracil nor
oxaliplatin) inhibit the differentiation of Treg cells from human
peripheral blood mononuclear cells stimulated with IL-2 and
TGF-b in vitro (Kan et al., 2012), suggesting that these chemo-
therapeutics may exert direct Treg cell-inhibitory functions.
Driven by the high production of angiogenic factors,
including VEGF, the tumor vasculature develops rapidly and
accumulates structural abnormalities such as tortuosity, dila-
tion, and hyperpermeability (Jain, 2005). These local alterations,
which result in patchy hypoperfusion, may increase tumor
infiltration by Treg cells and M2 macrophages. In addition,
high circulating levels of VEGF may (1) promote Treg cell
proliferation, (2) stimulate MDSC accumulation in peripheral
immune organs, and (3) inhibit the maturation of DC precur-
sors. These effects can be reversed by agents that selectively
target the VEGF-VEGFR signaling axis, such as VEGF-
blocking antibodies (e.g., bevacizumab), or inhibitors of
VEGFR tyrosine kinase activity (e.g., lenvatinib) (Goel et al.,
2011). These molecules ‘‘normalize’’ the tumor vasculature
and revert tumor-induced alterations of the peripheral immune
system, including the elevation of circulating Treg cells (Huang
et al., 2013).82 Immunity 39, July 25, 2013 ª2013 Elsevier Inc.Altogether, the findings reviewed here support the notion that
at least part of the therapeutic efficacy of successful antineo-
plastic agents originates from their capacity to functionally
interact with one or several components of the immune system.
Concluding Remarks
There is convincing preclinical and accumulating clinical evi-
dence in support of the notion that successful antineoplastic
therapies reinstate immunosurveillance. Thus, both conventional
chemotherapeutics and targeted anticancer agents appear to
stimulate the antigenicity of malignant cells, their immunoge-
nicity, or their susceptibility to immune attack. These alterations
are not inherent to the capacity of antineoplastic agents to kill
(or permanently block the proliferation of) cancer cells, but rather
reside in their potential to induce a cell death-independent stress
response that may mimic that elicited by viral infection. As
a constant leitmotif, anticancer agents that induce robust ER
stress responses and/or autophagymediate efficient immunosti-
mulation by directly acting on malignant cells (Kroemer et al.,
2013). In addition, chemotherapy can have various ancillary
effects on the immune system, ranging from a generalized
‘‘reset’’ as a result of severe lympho- and myelodepletion to
more subtle alterations in the equilibrium between effector
and suppressor cells. Several successful antineoplastic agents
seem to reinstate immunosurveillance by influencing the tumor-
host equilibrium at multiple levels. For instance, cyclophospha-
midenot only triggers the immunogenicdemiseofmalignant cells
but also stimulates the differentiation of Th17 cells and subverts
the immunosuppressive functions of Treg cells. This may reflect
the pleiotropic activity of compounds that act on ubiquitous
structures (such as microtubules for taxanes or topoisomerase
II and mitochondria for anthracyclines) or broadly expressed
targets (such as ABL, KIT, and PDGFR for imatinib).
We surmise that chemotherapeutic agents that have been
positively selected for their clinical efficacy are actually those
that most effectively reinstate cancer immunosurveillance.
Dose-intensification approaches, which often result in major
immunosuppressive side effects, have been largely unsuccess-
ful, and it is plausible that the doses and administration sched-
ules that are currently being used for chemotherapeutics have
been selected because they were compatible with anticancer
immune responses. Moreover, the fact that different tumor types
are nowadays treated with distinct therapeutic regimens might
reflect peculiarities in the immunological features of such neo-
plasms, extending beyond cancer cell-intrinsic properties and
pharmacokinetic issues. Nonetheless, the selection and optimi-
zation processes that have yielded current anticancer drugs
have been entirely empirical, and hence have systematically
neglected possible immune (side) effects. It is therefore tempting
to speculate that the introduction of immunological procedures
into the development of anticancer agents, including the system-
atic use of realistic animal models in which cancers evolve in an
immunocompetent setting, for instance, as well as the applica-
tion of suitable immunomonitoring techniques to patients, will
speed up the development of novel antineoplastic agents
(Figure 4). It is difficult to make firm recommendations on the
preferential use of genetically engineered versus engraftment
models of cancer, because both approaches have specific ad-
vantages and disadvantages. In particular, although engraftment
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Figure 4. Integrating Immunological Parameters into the
Development of Anticancer Agents
(A) The conventional pipeline for the development of novel antineoplastic
agents is based on the old vision that cancer would represent a merely cell-
intrinsic disease. In this setting, putative therapeutic effects mediated by the
immune system are neglected, resulting in high attrition rates, in particular
when candidate agents enter clinical trials.
(B) Testing the therapeutic efficacy of candidate antineoplastic drugs in
immunocompetent animal models will minimize the clinical development of
agents with unwarranted side effects on the immune system while promoting
that of compounds that reinstate anticancer immunosurveillance. Along similar
lines, carefully monitoring immunological parameters in cancer patients
enrolled in clinical trials is expected to guide the discovery of novel biomarkers,
the optimization of doses and schedules, and the rational design of combi-
natorial chemoimmunotherapeutic regimens.
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lesions generally offer more ‘‘realistic’’ scenarios than do en-
grafted tumors. Nonetheless, the tissue-wide overexpression
of an oncogene may overwhelm natural immunosurveillance
mechanisms. For example, Erbb2-driven murine breast cancers
respond to chemotherapy independently from the adaptive im-
mune system (Ciampricotti et al., 2012), contrasting withmultiple
clinical studies that underscore the contribution of tumor-infil-
trating lymphocytes to therapeutic outcome (DeNardo et al.,
2011; Denkert et al., 2010; Ladoire et al., 2011; Loi et al.,
2013a; Senovilla et al., 2012; West et al., 2011).
An in-depth characterization of the immunological effects of
currently used anticancer agentsmay pave the way to the design
of rational combination therapies in which maximal immunosti-mulation is sought by the simultaneous or sequential coadminis-
tration of several chemo- and immunotherapeutic agents. In
particular, agents acting on distinct facets of malignant cells
or the immune system (Figure 2) should stimulate antitumor
immune responses in a synergistic fashion. Thus, chemothera-
peutic agents that stimulate the antigenicity and immunogenicity
of malignant cells or increase their susceptibility to immune
attacks may be advantageously combined with immunothera-
peutic regimens designed to activate immune effectors or to
inhibit immunosuppressive mechanisms. Prominent examples
of the therapeutic potential of this approach include (1) the
sequential administration of doxorubicin, cyclophosphamide,
and an allogeneic granulocyte macrophage colony-stimulating
factor (GM-CSF)-secreting anticancer vaccine to breast carci-
noma patients (Emens et al., 2009), (2) the combination of pacli-
taxel with macrophage-depleting agents for the treatment of
breast cancer (DeNardo et al., 2011), and (3) the use of paclitaxel,
carboplatin, and ipilimumab as a first-line intervention against
advanced lung cancer (Lynch et al., 2012).
Similar to all other biological systems, immune responses
involve a limited number ofmolecules and cell types thatmediate
their effects in a highly context-dependent manner, like letters in
words and words in phrases. Thus, it would be a reductionist
(and probably futile) exercise to attribute general roles to single
entities with respect to inflammation-induced tumor progression
and anticancer immune responses (Coussens et al., 2013).
Rather, the same molecules and cell types may play ambiguous
roles depending on tumor type, immune contexture, and/or
precise therapeutic strategy. This is well exemplified by IL-1b,
whose neutralization negatively affects the outcome of anthracy-
cline-based chemotherapy, because IL-1b produced by DCs is
required for anticancer immune responses (Ghiringhelli et al.,
2009; Mattarollo et al., 2011), yet can improve the therapeutic
potential of 5-fluorouracil and gemcitabine, because IL-1b pro-
duced by MDSCs can participate in tumor-promoting inflamma-
tory reactions (Bruchard et al., 2013). Similarly, extracellular
HMGB1 generally boosts chemotherapy-elicited immune re-
sponses (Apetoh et al., 2007a), yet can also act as a proinflam-
matory factor that drives tumor progression (He et al., 2013).
Finally, IL-17 may have a dual influence on chemotherapy-eli-
cited immune responses against malignant cells: a positive one
if IL-17 is produced by gd T cells (Ma et al., 2011) and a negative
one when IL-17 is secreted by Th17 cells (Bruchard et al., 2013).
These complexities underscore the need for an ever more
profound comprehension of the dynamic changes in the tumor
microenvironment and in systemic immune responses as neo-
plasms evolve, progress, and respond to therapy. An improved
knowledge of these aspects will facilitate the rational design of
highly efficient, synergistic regimens that combine anticancer
agents and immunotherapies.ACKNOWLEDGMENTS
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